Home/iQure Pharma/Pawel Zolnierczyk

PZ

Pawel Zolnierczyk

CEO

Therapeutic Areas

Central Nervous System Epilepsy Neurodegeneration Pain

iQure Pharma Pipeline

Drug	Indication	Phase
iQ-007	Treatment-Resistant Epilepsy	Phase 1
Preclinical Programs	Neurodegeneration (e.g., Alzheimer's, Parkinson's) and Pain	Preclinical

Leadership Team at iQure Pharma

Prof. Krzysztof Kaminski

Inventor of iQ-007

Prof. Iris Loew-Friedrich, MD

Clinical and R&D Advisor

View full iQure Pharma profile